Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia
Sponsor: GlaxoSmithKline
A PHASE2 clinical study on CLL and Leukemia, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 12 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Apr 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .